PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
نویسندگان
چکیده
منابع مشابه
Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
INTRODUCTION New tyrosine kinase inhibitor treatments for chronic myeloid leukemia based on nilotinib, dasatinib and imatinib have improved patient quality of life and have turned chronic myeloid leukemia from a fatal disease into a chronic disease. OBJECTIVE To evaluate the cost-effectiveness of nilotinib, 600 mg, and dasatinib, 100 mg, each compared to imatinib, 400 mg, as first-line therap...
متن کاملFirst-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for chronic myeloid leukemia (CML) for almost 10 years. Dasatinib and nilotinib, two newer drugs with higher potency than imatinib against BCR-ABL and activity against most imatinib-resistant BCR-ABL mutations, have each shown superior efficacy compared with imatinib for first-line treatment of chronic-p...
متن کاملInvestigation of SMAD3 and SMAD4 genes expression in CML patients and K562 cell line and association with chronic myeloid leukemia
Aim and Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with cytogenetic characterization of the abnormal Philadelphia chromosome. This chromosome results from a reciprocal translocation between chromosomes 9 and 22. This is an important signaling pathway in the process of cancer cell proliferation and apoptosis, as well as the pathogenesis of TGF-β disease, i...
متن کاملIs imatinib still an acceptable first-line treatment for CML in chronic phase?
The introduction of the tyrosine kinase inhibitor (TKI) imatinib (Gleevec) into clinical practice resulted in a very dramatic prolongation of survival for most, but not all, patients with chronic myeloid leukemia in chronic phase (CML-CP). A leukemia with a median survival of about 5 years was transformed into one for which the survival in many cases promises to be comparable to that of normal ...
متن کاملEffectiveness and cost-effectiveness of imatinib for treatment of chronic myeloid leukaemia
inspected n = 213 Full text articles retrieved n = 17 Full text articles inspected n = 17 Articles for appraisal and data extraction n = 17 Excluded n = 196 Not primary research = 91 Not imatinib = 10 Not chronic phase CML = 20 Biological/preclinical/genetic studies = 46 Not first-line treatment of CML = 16 Animal studies = 2 Other = 11 (complications 9, outcome measures 2) Excluded n = 16 Biol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2004
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)65736-1